repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gout and Hyperuricemia
Conditions
Gout and Hyperuricemia
Trial Timeline
Jan 4, 2024 → Feb 16, 2024
NCT ID
NCT06196580About repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placebo
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Gout and Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT06196580. Target conditions include Gout and Hyperuricemia.
What happened to similar drugs?
12 of 20 similar drugs in Gout and Hyperuricemia were approved
Approved (12) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06196580 | Phase 1 | Completed |
Competing Products
20 competing products in Gout and Hyperuricemia